{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:03:22Z","timestamp":1762459402471},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Australasian Leukaemia and Lymphoma Group and Novartis"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.beha.2016.10.006","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T18:45:55Z","timestamp":1476989155000},"page":"284-294","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monitoring and defining early response: Where to draw the line?"],"prefix":"10.1016","volume":"29","author":[{"given":"Susan","family":"Branford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"122","key":"10.1016\/j.beha.2016.10.006_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib2","series-title":"NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Version 1","year":"2016"},{"key":"10.1016\/j.beha.2016.10.006_bib3","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1182\/blood-2010-03-273979","article-title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)","volume":"116","author":"Hughes","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib4","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.006_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib7","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib8","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","article-title":"Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials","volume":"112","author":"Branford","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/leu.2009.168","article-title":"Harmonization of molecular monitoring of CML therapy in Europe","volume":"23","author":"Muller","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib10","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-2141.2011.08603.x","article-title":"Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia","volume":"153","author":"Foroni","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2353\/jmoldx.2007.060134","article-title":"Inter-laboratory comparison of chronic myeloid leukemia minimal residual disease monitoring: summary and recommendations","volume":"9","author":"Zhang","year":"2007","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.beha.2016.10.006_bib12","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1182\/blood.V92.11.4059","article-title":"Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha","volume":"92","author":"Mahon","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.006_bib14","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.006_bib15","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib16","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"NEJM"},{"key":"10.1016\/j.beha.2016.10.006_bib17","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.006_bib18","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.006_bib19","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800 mg\/d versus 400 mg\/d versus 400 mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.006_bib20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Brummendorf","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib22","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1365-2141.2002.03705.x","article-title":"Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia","volume":"118","author":"Wang","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib23","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1038\/sj.leu.2402680","article-title":"Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha","volume":"16","author":"Merx","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1046\/j.1365-2141.2003.04200.x","article-title":"The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia","volume":"120","author":"Wang","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib25","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib26","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib28","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.006_bib29","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib30","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib31","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood-2014-05-578567","article-title":"Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study","volume":"124","author":"Millot","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib32","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.3109\/10428194.2014.974047","article-title":"Molecular responses at 3 and 6 months after switching to a second-generation tyrosine kinase inhibitor are complementary and predictive of long-term outcomes in patients with chronic myeloid leukemia who fail imatinib","volume":"56","author":"Boquimpani","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2016.10.006_bib33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib34","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/ajh.23707","article-title":"BCR\/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase","volume":"89","author":"Kim","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2016.10.006_bib35","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1373\/clinchem.2003.026161","article-title":"Properties of the reverse transcription reaction in mRNA quantification","volume":"50","author":"Stahlberg","year":"2004","journal-title":"Clin Chem"},{"key":"10.1016\/j.beha.2016.10.006_bib37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mam.2005.12.003","article-title":"RNA integrity and the effect on the real-time qRT-PCR performance","volume":"27","author":"Fleige","year":"2005","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.beha.2016.10.006_bib38","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/sj.leu.2404983","article-title":"Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories","volume":"22","author":"M\u00fcller","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib39","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3324\/haematol.2013.090282","article-title":"Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months","volume":"98","author":"Nazha","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.006_bib40","first-page":"254","article-title":"Any BCR-ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months","volume":"122","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib41","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib42","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23923","article-title":"Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: results of the D-first study of Kanto CML study group","volume":"90","author":"Iriyama","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.beha.2016.10.006_bib43","doi-asserted-by":"crossref","first-page":"e106250","DOI":"10.1371\/journal.pone.0106250","article-title":"Major molecular response achievement in CML patients can be predicted by BCR-ABL1\/ABL1 or BCR-ABL1\/GUS ratio at an earlier time point of follow-up than currently recommended","volume":"9","author":"Huet","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.beha.2016.10.006_bib44","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib45","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2011-11-393041","article-title":"BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse\u00a0compared with the BCR-ABL1 fold rise: implications for monitoring and management","volume":"119","author":"Branford","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib46","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/sj.leu.2402922","article-title":"Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects","volume":"17","author":"van der Velden","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib47","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","article-title":"Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using \u2018real-time\u2019 quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) \u2013 a Europe against cancer program","volume":"17","author":"Beillard","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib48","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1046\/j.1365-2141.1999.01749.x","article-title":"Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics","volume":"107","author":"Branford","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib50","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V81.1.158.158","article-title":"The ABL-BCR fusion gene is expressed in chronic myeloid leukemia","volume":"81","author":"Melo","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1046\/j.1365-2141.1996.00350.x","article-title":"Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia","volume":"92","author":"Melo","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2016.10.006_bib52","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood.V98.9.2879","article-title":"ABL-BCR expression does not correlate with deletions on the derivative chromosome 9 or survival in chronic myeloid leukemia","volume":"98","author":"de la Fuente","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib53","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe against cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib54","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/sj.leu.2401566","article-title":"Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR","volume":"13","author":"Emig","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.leu.2402329","article-title":"Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases","volume":"16","author":"Schoch","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.006_bib56","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1182\/blood.V122.21.3993.3993","article-title":"Relative ratio of BCR-ABL1 transcript clearance improves the prognostic value ff single PCR assessment at the 3 and 6 month time points in patients with chronic myeloid leukemia in chronic phase treated in the Dasision study","volume":"122","author":"Quint\u00e1s-Cardama","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.006_bib57","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s10147-011-0328-x","article-title":"Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan","volume":"17","author":"Yoshida","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.006_bib58","series-title":"Analysis of the relationship between dose and BCR-ABL halving time in CP-CML patients treated with ponatinib or imatinib","author":"Pritchard","year":"2015"},{"key":"10.1016\/j.beha.2016.10.006_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1182\/blood.V122.21.95.95","article-title":"Switching to nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with suboptimal cytogenetic response (CyR) on imatinib: first results of the LASOR Trial","volume":"123","author":"Cortes","year":"2013","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692616300597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T20:42:15Z","timestamp":1601152935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692616300597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1521692616300597"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.006","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring and defining early response: Where to draw the line?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}